Search research articles
Contact Us
Filters
Showing results (51-60 of 67) with videos related to
Page
of 7
Sort By:
Biorxiv : the Preprint Server for Biology
|
May 20, 2021
Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19
Paulina Kaplonek, Chuangqi Wang, Yannic Bartsch, et al.
Nature Medicine
|
October 5, 2010
Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF
Michael Quigley, Florencia Pereyra, Björn Nilsson, et al.
The Lancet. HIV
|
October 6, 2023
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial
Magdalena E Sobieszczyk, Sharon Mannheimer, Carmen A Paez, et al.
Cell Reports
|
December 16, 2020
HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound
Rasmus Offersen, Wen-Han Yu, Eileen P Scully, et al.
Scientific Reports
|
April 8, 2025
Intranasal administration of a panreactive influenza antibody reveals Fc-independent mode of protection
Anna L Beukenhorst, Keira L Rice, Jacopo Frallicciardi, et al.
Nature Medicine
|
September 12, 2024
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial
Boris Julg, Victoria E K Walker-Sperling, Kshitij Wagh, et al.
Pharmaceutics
|
May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
Bryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Science Translational Medicine
|
September 8, 2017
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge
Boris Julg, Lawrence J Tartaglia, Brandon F Keele, et al.
NPJ Vaccines
|
May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy
Boris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
Viruses
|
November 27, 2021
Epidemiological and Immunological Features of Obesity and SARS-CoV-2
Eric J Nilles, Sameed M Siddiqui, Stephanie Fischinger, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 67) with videos related to
Sort By:
Page
of 7
Biorxiv : the Preprint Server for Biology
|
May 20, 2021
Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19
Paulina Kaplonek, Chuangqi Wang, Yannic Bartsch, et al.
Nature Medicine
|
October 5, 2010
Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF
Michael Quigley, Florencia Pereyra, Björn Nilsson, et al.
The Lancet. HIV
|
October 6, 2023
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial
Magdalena E Sobieszczyk, Sharon Mannheimer, Carmen A Paez, et al.
Cell Reports
|
December 16, 2020
HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound
Rasmus Offersen, Wen-Han Yu, Eileen P Scully, et al.
Scientific Reports
|
April 8, 2025
Intranasal administration of a panreactive influenza antibody reveals Fc-independent mode of protection
Anna L Beukenhorst, Keira L Rice, Jacopo Frallicciardi, et al.
Nature Medicine
|
September 12, 2024
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial
Boris Julg, Victoria E K Walker-Sperling, Kshitij Wagh, et al.
Pharmaceutics
|
May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
Bryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Science Translational Medicine
|
September 8, 2017
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge
Boris Julg, Lawrence J Tartaglia, Brandon F Keele, et al.
NPJ Vaccines
|
May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy
Boris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
Viruses
|
November 27, 2021
Epidemiological and Immunological Features of Obesity and SARS-CoV-2
Eric J Nilles, Sameed M Siddiqui, Stephanie Fischinger, et al.
Page
of 7